

GLAXOSMITHKLINE PLC  
Form 6-K  
February 16, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 16 February 2018

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes  No

GlaxoSmithKline plc (the 'Company')  
Conditional Share Awards

This notification sets out the vesting details of awards over Ordinary Shares and American Depositary Shares ('ADS') made in 2015 under the GlaxoSmithKline Performance Share Plan ('PSP'), which were subject to relevant business performance conditions. The three-year performance period for the 2015 awards commenced on 1 January 2015 and ended on 31 December 2017.

The performance measure vesting details for those Persons Discharging Managerial Responsibilities ('PDMRs') who received awards in 2015 are set out in the following table.

Portion of the Award	Measure and Outcome	Outcome and Vesting Level	
		% of maximum	% of award
1/3rd	Adjusted Free Cash Flow - For the three-year period, the Company achieved Adjusted Free Cash Flow calculated in accordance with the principles for the measure of £12.47bn which is above the threshold level of £11.48bn.	63	21
1/3rd	Total Shareholder Return - For the three years ending 31 December 2017, the Company's Total Shareholder Return ranked 5th, which is above the threshold vesting level against a comparator group of 10 global pharmaceutical companies including GSK.	44	14.67
1/3rd	R&D New Products - For the three-year period, the Company achieved New Product sales calculated in accordance with the principles for the measure of £11.266bn, which is above the maximum vesting level of £7.912bn (the threshold level was £6.474bn).	100	33.33
	Total vesting for 2015 award		69%
	Lapsed		31%

The notifications that follow are for awards made to PDMRs and detail the PSP conditional awards that vested, including dividends accrued, on 15 February 2018. The balance of the award made to each PDMR has lapsed.

The closing share prices of an Ordinary Share and of an ADS of GlaxoSmithKline plc at the point of vesting on 15 February 2018 were £13.004 and \$37.31.

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Ms E Walmsley
  - b) Position/status Chief Executive Officer
  - c) Initial notification/ Initial notification

amendment

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary Shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
  - b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2015 under the Company's 2009 Performance Share Plan.
  - c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£0.00	91,430
£0.00	47,391

Aggregated information

- d) Aggregated volume 138,821
- Price £0.00
- e) Date of the transaction 2018-02-15
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr R Connor
  - b) Position/status President, Global Manufacturing & Supply
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary Shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882

b) Nature of the transaction	The number of Ordinary Shares vesting on awards granted in 2015 under the Company's 2009 Performance Share Plan.	
c) Price(s) and volume(s)	Price(s) £0.00	Volume(s) 71,160
d) Aggregated information	n/a (single transaction)	
e) Date of the transaction	2018-02-15	
f) Place of the transaction	London Stock Exchange (XLON)	

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr L Debruyne
  - b) Position/status President, Global Vaccines
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary Shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882

b) Nature of the transaction	The number of Ordinary Shares vesting on awards granted in 2015 under the Company's 2009 Performance Share Plan.	
c) Price(s) and volume(s)	Price(s) £0.00	Volume(s) 18,203
d) Aggregated information	n/a (single transaction)	
e) Date of the transaction	2018-02-15	
f) Place of the transaction	London Stock Exchange (XLON)	

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr S Dingemans
  - b) Position/status Chief Financial Officer
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary Shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
  - b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2015 under the Company's 2009 Performance Share Plan. These shares are subject to a two-year holding period to end in 2020.
  - c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£0.00	154,763
  - d) Aggregated information n/a (single transaction)
  - e) Date of the transaction 2018-02-15
  - f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr N Hirons
  - b) Position/status SVP, Global Ethics and Compliance
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
- 3.

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary Shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b) Nature of the transaction	The number of Ordinary Shares vesting on awards granted in 2015 under the Company's 2009 Performance Share Plan.
c) Price(s) and volume(s)	Price(s)      Volume(s) £0.00          34,502
d) Aggregated information	n/a (single transaction)
e) Date of the transaction	2018-02-15
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr B McNamara
b) Position/status	CEO, GSK Consumer Healthcare
c) Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	GlaxoSmithKline plc American Depositary Shares ('ADSs') ISIN: US37733W1053
b) Nature of the transaction	The number of ADSs vesting on awards granted in 2015 under the Company's 2009 Performance Share Plan and which were made to compensate for the value of awards forfeited on completion of the Joint

Venture with Novartis.

	Price(s)	Volume(s)
c) Price(s) and volume(s)	\$0.00	24,345
	\$0.00	4,871

Aggregated information

d) Aggregated volume	29,216
Price	\$0.00
e) Date of the transaction	2018-02-15
f) Place of the transaction	New York Stock Exchange (XNYS)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr D Redfern
b) Position/status	Chief Strategy Officer
c) Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary Shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
--	--

b) Nature of the transaction	The number of Ordinary Shares vesting on awards granted in 2015 under the Company's 2009 Performance Share Plan.
------------------------------	--

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£0.00	56,605

Aggregated information

d) Aggregated volume	n/a (single transaction)
Price	
e) Date of the transaction	2018-02-15
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Ms C Thomas
  - b) Position/status SVP, Human Resources
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary Shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
  - b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2015 under the Company's 2009 Performance Share Plan.
  - c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£0.00	75,473
  - d) Aggregated information n/a (single transaction)
  - e) Date of the transaction 2018-02-15
  - f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr P Thomson
  - b) Position/status President, Global Affairs
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary Shares of 25 pence each ('Ordinary Shares')



ISIN: GB0009252882

b) Nature of the transaction	The number of Ordinary Shares vesting on awards granted in 2015 under the Company's 2009 Performance Share Plan.	
c) Price(s) and volume(s)	Price(s)	Volume(s)
Aggregated information	£0.00	43,667
d) Aggregated volume Price	n/a (single transaction)	
e) Date of the transaction	2018-02-15	
f) Place of the transaction	London Stock Exchange (XLON)	
1. Details of PDMR/person closely associated with them ('PCA')		
a) Name	Mr D Troy	
b) Position/status	SVP & General Counsel	
c) Initial notification/ amendment	Initial notification	
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a) Name	GlaxoSmithKline plc	
b) LEI	5493000HZTVUYLO1D793	
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a) Description of the financial instrument	GlaxoSmithKline plc American Depositary Shares ('ADSs') ISIN: US37733W1053	
b) Nature of the transaction	The number of ADSs vesting on awards granted in 2015 under the Company's 2009 Performance Share Plan.	
c) Price(s) and volume(s)	Price(s)	Volume(s)
Aggregated information	\$0.00	66,334
d) Aggregated volume Price	n/a (single transaction)	
e) Date of the transaction	2018-02-15	
f) Place of the transaction	New York Stock Exchange (XNYS)	

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Dr P Vallance
  - b) Position/status Outgoing President, R&D
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary Shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
  - b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2015 under the Company's 2009 Performance Share Plan.
  - c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£0.00	156,984
  - d) Aggregated information n/a (single transaction)
  - e) Date of the transaction 2018-02-15
  - f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mrs V Whyte
  - b) Position/status Company Secretary
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

a) Description of the financial instrument	Ordinary shares of 25 pence each 'Ordinary Shares' ISIN: GB0009252882
b) Nature of the transaction	The number of Ordinary Shares vesting on awards granted in 2015 under the Company's 2009 Performance Share Plan.
c) Price(s) and volume(s)	Price(s)      Volume(s) £0.00          9,667
d) Aggregated information	n/a (single transaction)
e) Date of the transaction	2018-02-15
f) Place of the transaction	London Stock Exchange (XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: February 16, 2018

By: VICTORIA WHYTE  
-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc